SNTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Senti Biosciences Inc (SNTI) is not a strong buy for a beginner, long-term investor at this time. The stock shows no clear technical signals, has weak financial performance, and lacks significant positive catalysts. While the company's innovative pipeline and analyst optimism about its therapies are promising, the cash runway concerns and lack of trading momentum make this a hold rather than a buy.
The MACD is slightly positive but contracting, RSI is neutral at 47.144, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 0.931, with support at 0.864 and resistance at 0.997. Overall, the technical indicators suggest a lack of strong momentum in either direction.
The company is advancing its Gene Circuit platform for cancer therapies, with positive preclinical results and ongoing Phase I trials showing encouraging efficacy. Analysts have raised the price target to $13, reflecting optimism about the company's potential.
The company's cash runway remains a concern, as highlighted by analysts. Financial performance in Q3 2025 was weak, with a significant drop in net income (-37.21% YoY) and EPS (-89.06% YoY). Trading sentiment from hedge funds and insiders is neutral, with no significant activity.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$18.13M (-37.21% YoY), and a sharp decline in EPS (-89.06% YoY). Gross margin remained at 0%. Overall, the financials indicate poor performance with no signs of immediate improvement.
Chardan raised the price target to $13 from $12 and maintained a Buy rating, citing positive data from the Phase I study of SENTI-202. However, the analyst also noted concerns about the company's cash runway, which could weigh on the stock.
